Jildeh Toufic R, Abbas Muhammad J, Buckley Patrick, Okoroha Kelechi R
Department of Orthopaedic Surgery, Henry Ford Health System, 2799 W. Grand Blvd, Detroit, MI, 48202, USA.
Curr Rev Musculoskelet Med. 2021 Apr;14(2):145-154. doi: 10.1007/s12178-021-09695-7. Epub 2021 Jan 23.
A wide array of nonoperative modalities to treat hip pain are aimed at restoring and maintaining the structural and physiologic characteristics of the joint. The purpose of this review is to describe the current understanding of biologics in hip pathology by providing an evidence-based overview of treatment modalities available for orthopedic surgeons.
The use of biologics as a primary treatment or adjunct to traditional management has shown encouraging results for the treatment of hip pain. Studies have demonstrated safety with minimal complications when using platelet rich plasma, hyaluronic acid, or stem cells to treat hip pain caused by osteoarthritis, femoroacetabular impingement syndrome, tendinopathy, or osteonecrosis of the femoral head. Several studies have been able to demonstrate meaningful clinical results that can improve treatment standards for hip pain; however, more work must be performed to better delineate the appropriate protocols, indications, and limitations of each modality. Recent advances have inspired renewed interest in biologics for patients with hip pain. We present a concise review of platelet rich plasma, hyaluronic acid, stem cells, and matrix metalloprotease inhibitors and their applicability to hip preservation surgery.
多种治疗髋关节疼痛的非手术方法旨在恢复和维持关节的结构及生理特性。本综述的目的是通过为骨科医生提供现有治疗方式的循证概述，来描述目前对生物制剂在髋关节病变中的理解。
将生物制剂作为主要治疗手段或传统治疗的辅助手段，在治疗髋关节疼痛方面已显示出令人鼓舞的结果。研究表明，使用富血小板血浆、透明质酸或干细胞治疗由骨关节炎、股骨髋臼撞击综合征、肌腱病或股骨头坏死引起的髋关节疼痛时，安全性良好，并发症极少。多项研究已能够证明有意义的临床结果，可提高髋关节疼痛的治疗标准；然而，还必须开展更多工作，以更好地界定每种治疗方式的适当方案、适应证和局限性。最近的进展激发了人们对生物制剂治疗髋关节疼痛患者的新兴趣。我们简要综述富血小板血浆、透明质酸、干细胞和基质金属蛋白酶抑制剂及其在髋关节保留手术中的适用性。
